Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

Jüttner, FM; Smolle, J; Popper, H; Pinter, HH; Friehs, G.
Perioperative adjuvant chemotherapy with bleomycin in bronchogenic squamous cell cancer. A prospective randomized study
Onkologie. 1986; 9(5):250-253 Doi: 10.1159/000216021
Web of Science PubMed FullText FullText_MUG Google Scholar

Leading authors Med Uni Graz: Smolle-Juettner Freyja-Maria
Co-authors Med Uni Graz: Pinter Hans; Popper Helmuth; Smolle Josef
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Bleomycin (BLM) was given perioperatively and 3 and 6 months postoperatively in a dosage of 150 mg per course (total: 450 mg) to 37 patients with surgically resectable squamous-cell lung cancer. 37 randomized control patients with resectable squamous-cell lung cancer were compared to the chemotherapy-group. 5-year overall survival of the BLM group was 46.3%, that of the controls 40.5% (Mantel-Haenszel test; p greater than 0.05). BLM-treated stage I showed a 5-year survival of 47.9% (controls: 55%), BLM stage II 50% (controls: 33.3%), BLM stage III 40% (controls: 21.4%). The difference is not statistically significant. No severe adverse effects of therapy on either wound healing, or perioperative mortality of lung function were observed.
Find related publications in this database (using NLM MeSH Indexing): Bleomycin - therapeutic use; Carcinoma, Bronchogenic - drug therapy; Carcinoma, Squamous Cell - drug therapy; Clinical Trials - drug therapy; Combined Modality Therapy - drug therapy; Follow-Up Studies - drug therapy; Humans - drug therapy; Lung Neoplasms - drug therapy; Random Allocation - drug therapy